CME partially restores operations with EBS foreign exchange platform reopening
Introduction & Market Context
Indorama Ventures PCL (IVL) presented its third-quarter 2025 financial results on November 11, 2025, revealing significant challenges across its global operations. The Thailand-based chemical producer faces what management described as "unprecedented industry turbulence" characterized by geopolitical uncertainty, overcapacity, weak downstream demand, and structural pressures, particularly in Europe.
The company's stock has continued to decline following the earnings release, hitting a 52-week low of 16.5 before settling at 17.0, representing a 1.18% decline in the most recent trading session. Year-to-date, the stock has lost nearly 30% of its value as investors react to deteriorating financial performance.
Quarterly Performance Highlights
IVL reported adjusted EBITDA of $279 million for Q3 2025, representing a 15% decrease quarter-over-quarter and a substantial 35% decline year-over-year. Sales volume fell to 3.22 million tons, down 3% from the previous quarter and 9% compared to the same period last year, which the company attributed to planned PO/MTBE turnaround, unplanned outages, and lower volumes from optimized PTA assets in Canada.
As shown in the following comprehensive business results summary:
Revenue declined to $3.39 billion, representing a 4% drop quarter-over-quarter and a 14% decrease year-over-year. The company reported a net loss of THB 818 million on a reported basis, though it presented an adjusted net profit of THB 177 million, which still reflected a 70% decrease from the previous quarter and a dramatic 94% decline year-over-year.
Despite these challenges, IVL highlighted its operating cash flow of $985 million for the first nine months of 2025, with an EBITDA conversion rate of 121%, driven by efficient working capital management.
Regional and Segment Performance Analysis
The company's presentation revealed declining performance across all geographic regions, with Asia continuing to be the strongest contributor despite challenges.
The regional breakdown of adjusted EBITDA shows significant variances in performance:
Asia remained the largest contributor with $182 million in Q3 2025, though this represented a decline from previous quarters. EMEA (Europe, Middle East, and Africa) generated $71 million with the highest margin at 11%, while the Americas struggled significantly with just $25 million in EBITDA and a concerning 1% margin.
When examining performance by business segments, similar downward trends were evident:
The Fibers segment generated $182 million in adjusted EBITDA (8% margin), followed by Indovinya with $78 million (12% margin) and CPET & Indovida with $31 million (4% margin). All segments showed year-over-year declines, with the Combined PET segment particularly affected.
A deeper look at the Combined PET segment reveals the challenges faced:
The segment's adjusted EBITDA fell 39% year-over-year and 17% quarter-over-quarter, with Intermediate Chemicals remaining the primary contributor at $124 million, while Integrated PET showed some improvement at $15 million.
Cost Reduction and Optimization Initiatives
In response to these challenging market conditions, IVL has accelerated its cost-cutting and asset optimization efforts. The company has rationalized 2.7 million metric tons of capacity and expects over $200 million in proceeds from land and property sales in 2026.
The company's asset optimization strategy includes:
These efforts have yielded tangible results in fixed cost reduction:
IVL has reduced its fixed costs from $2.42 billion in the last twelve months ending Q3 2023 to $2.28 billion in the comparable period of 2025, representing savings of approximately $140 million.
Management has outlined additional initiatives under the "NorthStar Program" for 2026-27, targeting over $50 million in fixed cost run-rate reduction by the end of 2027 through organizational restructuring, cost reduction, and digital enablement.
Financial Position and Debt Management
IVL's net debt increased to $7.25 billion as of September 2025, up from $7.0 billion at the end of 2024. The company's debt bridge shows the various factors affecting its financial position:
While the company generated $985 million in operating cash flow during the first nine months of 2025, this was partially offset by maintenance capex ($276 million), net financing costs ($284 million), and the EPL acquisition ($221 million).
The company's working capital management has shown mixed results, with net working capital decreasing to $1,106 million in Q3 2025 from $1,186 million in Q3 2024, but working capital days increasing to 93 days from 87 days over the same period.
Forward-Looking Statements
Looking ahead, IVL management expects significant industry reshaping through regulatory intervention and consolidation via partnerships and M&A over the next 12-24 months. The company is positioning itself for this transition by:
1. Focusing on cost discipline, productivity improvements, and footprint optimization, especially in Europe
2. Advancing digitalization, sustainability, and innovation initiatives
3. Pursuing strategic collaborations and portfolio realignment
4. Strengthening its balance sheet to improve earnings quality
However, these forward-looking statements contrast with the market's current assessment, as evidenced by the stock's continued decline to 52-week lows. Investors appear concerned about the company's ability to navigate the current downturn, particularly given its high debt levels and the significant miss in earnings expectations, with actual EPS of -0.19 falling far short of the forecasted 0.29.
As the chemical industry continues to face headwinds from overcapacity and weak demand, IVL's ability to execute its cost-cutting and optimization strategies will be crucial in determining whether it can stabilize its financial performance and regain investor confidence in the coming quarters.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.